Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for Platelet Recovery in Stem Cell Transplant
NCT01927731Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2013
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of eltrombopag in Thrombocytopenia (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants That Achieved Platelet Engraftment Greater Than 50K/ul at Day 60. Started Oct 2013; status: completed.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT01927731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01927731.